semaglutide approval for weight loss The FDA has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, and long-term weight maintenance in certain adult patients—in just 54 days from filing A big win for Wegovy:
Description
[PubMed: 18539916] 28

placebo, 8.8%), nor in the incidence of level 2 or 3 hypoglycemia, the researchers wrote
Weight Loss Effectiveness Based on clinical trial data, there is a clear progression in weight loss effectiveness across the three classes
GLP1 Agents and Breast Cancer in Clinical Studies The largest analysis of the impact of GLP1RAs and cancer risk is a retrospective cohort study of over 1.6 million T2D patients without prior diagnoses of obesityassociated cancers (OACs) treated with GLP1 RAs in addition to other hypoglycemic agents from March 2005 to November 2018
